Lamivudine resistance in naïve chronic hepatitis B patients

Engin ALTINKAYA

doi:https://doi.org/10.7197/cmj.vi.617023

Makale detayları

Lamivudine resistance in naïve chronic hepatitis B patients

Yazarlar:

Engin ALTINKAYA

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Cumhuriyet Medical Journal 2019 Vol.41 Issue 3, pp.524-530

Belge Tipi:

Makale

Yayın Tarihi:

9/2019

Belge Dili:

İngilizce

Document ID (Org No.):

2000922488

DOI:

https://doi.org/10.7197/cmj.vi.617023

Özet:

 


Objective:
Prevalence of lamivudine resistance in treatment-naïve hepatitis B patients shows variation among populations. The present study aimed to determine the prevalence of lamivudine
resistance in treatment-naïve chronic hepatitis B (CHB) patients followed in
Turkish population. 


Method:
The study comprised 71
chronic hepatitis B patients that have never received treatment for chronic
hepatitis B infection before (treatment-naïve). HBV DNA was detected
quantitatively by real-time polymerase chain reaction (RT-PCR) method in serum
samples collected from the patients. Sequence analysis and reverse
hybridization by string method were used to determine Lamivudine motif mutants.
Liver biopsy was performed in all patients. Serum samples collected were used
to determine HBeAg and anti-HBeAb levels.


Results:
Of the 71 patients
participated in the study. Mutation was detected in a total of 8 patients and
the prevalence was 11.3% (8/71). The prevalence of mutation was 8.3% (4/48) in
HBeAg-negative patients and it was lower than HBeAg-positive patients, in whom
the prevalence was 17% (4/23) (p=0.01). Comparing the patients with and without
mutation in terms of demographic characteristics, ALT levels, HAI and fibrosis
scores, no statistically significant difference was determined (p=0.29).









Conclusions:
In the present study, the
prevalence of mutation was 11.3% in treatment-naïve chronic hepatitis B
patients.  Therefore, determining local
prevalence for all populations and planning the treatment accordingly may
prevent future complications and thereby enhance efficacy of treatment. Choosing drugs with low resistance
profile and starting treatment considering this resistance.


.

Makale detayları

Lamivudine resistance in naïve chronic hepatitis B patients

Yazarlar: Engin ALTINKAYA

Ana Başlıklar: Sağlık teşvikleri

Dergi: Cumhuriyet Medical Journal 2019 Vol.41 Issue 3, pp.524-530

Belge Tipi: Makale

Yayın Tarihi: 9/2019

Belge Dili: İngilizce

Document ID (Org No.): 2000922488

DOI: https://doi.org/10.7197/cmj.vi.617023

Sayı

Yazarlar:

Engin ALTINKAYA

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Cumhuriyet Medical Journal 2019 Vol.41 Issue 3, pp.524-530

Belge Tipi:

Makale

Yayın Tarihi:

9/2019

Belge Dili:

İngilizce

Document ID (Org No.):

2000922488

DOI:

https://doi.org/10.7197/cmj.vi.617023